Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

It is hypothesised that associations between adverse drug reactions and specific alleles of the human leukocyte antigens arise due to specific interactions between the human leukocyte antigen molecules and the causative drug that stimulate immune responses targeting drug exposed tissues. To date this has only been definitively demonstrated for abacavir, an antiretroviral that causes a systemic adverse drug reaction, abacavir hypersensitivity syndrome, solely in HLA-B*57:01+ individuals. Whilst this has informed the modification of abacavir to remove immunogenicity, there remains an imperative to define other interactions between drugs and specific HLA in order to understand the scope of interactions that can drive T cell mediated drug hypersensitivity. Here we review the current state of understanding of these interactions.

Original languageEnglish
Pages (from-to)31-40
Number of pages10
JournalCurrent Opinion in Immunology
Volume42
DOIs
Publication statusPublished - Oct 2016

Cite this

@article{bd82f1446f9b4f9ca1fd1da19d29240d,
title = "Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions",
abstract = "It is hypothesised that associations between adverse drug reactions and specific alleles of the human leukocyte antigens arise due to specific interactions between the human leukocyte antigen molecules and the causative drug that stimulate immune responses targeting drug exposed tissues. To date this has only been definitively demonstrated for abacavir, an antiretroviral that causes a systemic adverse drug reaction, abacavir hypersensitivity syndrome, solely in HLA-B*57:01+ individuals. Whilst this has informed the modification of abacavir to remove immunogenicity, there remains an imperative to define other interactions between drugs and specific HLA in order to understand the scope of interactions that can drive T cell mediated drug hypersensitivity. Here we review the current state of understanding of these interactions.",
author = "Illing, {Patricia T} and Mifsud, {Nicole A} and Purcell, {Anthony W}",
year = "2016",
month = "10",
doi = "10.1016/j.coi.2016.05.003",
language = "English",
volume = "42",
pages = "31--40",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier",

}

Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions. / Illing, Patricia T; Mifsud, Nicole A; Purcell, Anthony W.

In: Current Opinion in Immunology, Vol. 42, 10.2016, p. 31-40.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions

AU - Illing, Patricia T

AU - Mifsud, Nicole A

AU - Purcell, Anthony W

PY - 2016/10

Y1 - 2016/10

N2 - It is hypothesised that associations between adverse drug reactions and specific alleles of the human leukocyte antigens arise due to specific interactions between the human leukocyte antigen molecules and the causative drug that stimulate immune responses targeting drug exposed tissues. To date this has only been definitively demonstrated for abacavir, an antiretroviral that causes a systemic adverse drug reaction, abacavir hypersensitivity syndrome, solely in HLA-B*57:01+ individuals. Whilst this has informed the modification of abacavir to remove immunogenicity, there remains an imperative to define other interactions between drugs and specific HLA in order to understand the scope of interactions that can drive T cell mediated drug hypersensitivity. Here we review the current state of understanding of these interactions.

AB - It is hypothesised that associations between adverse drug reactions and specific alleles of the human leukocyte antigens arise due to specific interactions between the human leukocyte antigen molecules and the causative drug that stimulate immune responses targeting drug exposed tissues. To date this has only been definitively demonstrated for abacavir, an antiretroviral that causes a systemic adverse drug reaction, abacavir hypersensitivity syndrome, solely in HLA-B*57:01+ individuals. Whilst this has informed the modification of abacavir to remove immunogenicity, there remains an imperative to define other interactions between drugs and specific HLA in order to understand the scope of interactions that can drive T cell mediated drug hypersensitivity. Here we review the current state of understanding of these interactions.

UR - http://www.scopus.com/inward/record.url?scp=84971265267&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2016.05.003

DO - 10.1016/j.coi.2016.05.003

M3 - Review Article

VL - 42

SP - 31

EP - 40

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

ER -